^
Association details:
| Biomarker: | MSLN overexpression + TP53 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | gavocabtagene autoleucel (TC-210) (T-cell stimulant, Mesothelin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
959O - Gavocabtagene autoleucel (gavo-cel, TC-210) dose escalation in refractory mesothelin-expressing solid tumors
Published date:
09/13/2021
Excerpt:
Eligibility required central confirmation of 2+ or 3+ MSLN expression by IHC in ≥50% of tumor cells....As of April 28th, 2021, 17 pts (12 MPM, 4 ovarian, 1 ChoCa) had received a single IV dose of gavo-cel at 5x107/m2....Two pts with ICI-refractory MPM and 1 with TP53-mutated platinum-resistant ovarian cancer had a PR (ORR 25%), including 1 MPM with a complete metabolic response by PET.
Trial ID:
